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ABSTRACT 
Microvesicles can transfer their contents, proteins and RNA, to target cells and thereby transform them. This 
may induce apoptosis or survival depending on cell origin and the target cell. In this study, we investigate the 
effect of leukemic cell microvesicles on umbilical cord blood hematopoietic stem cells to seek evidence of apop-
tosis or cell survival. Microvesicles were isolated from both healthy donor bone marrow samples and Jurkat cells 
by ultra-centrifugation and were added to hematopoietic stem cells sorted from umbilical cord blood samples by 
magnetic associated cell sorting (MACS) technique. After 7 days, cell count, cell viability, flow cytometry anal-
ysis for hematopoietic stem cell markers and qPCR for P53 gene expression were performed. The results showed 
higher cell number, higher cell viability rate and lower P53 gene expression in leukemia group in comparison 
with normal and control groups. Also, CD34 expression as the most important hematopoietic stem cell marker, 
did not change during the treatment and lineage differentiation was not observed. In conclusion, this study 
showed anti-apoptotic effect of leukemia cell derived microvesicles on umbilical cord blood hematopoietic stem 
cells. 
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INTRODUCTION 
Microvesicles are small (0.05-1 µm) 
membrane-bound particles released by dif-
ferent cells including both healthy and tumor 
types (Taylor and Gercel-Taylor, 2011; 
Mathivanan et al., 2010; Camussi et al., 
2010). They contain proteins, different kinds 
of RNA, lipids and organelles from the cells 
of origin to activate target cells, directly 
(Skog et al., 2008; Mitchell et al., 2008; Gi-
lad et al., 2008). 
Microvesicles are involved in different 
(patho)physiological processes in the body 
such as cell survival (Hussein et al., 2007; 
Shedden et al., 2003), escape from the im-
mune system (Whitlow and Klein, 1997; 
Hakulinen et al., 2004), angiogenesis (Tes-
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selaar et al., 2007; Rauch and Antoniak, 
2007) and metastasis (Al-Nedawi et al., 
2008; Skog et al., 2008). These effects are 
based on a) microvesicles’ specific recep-
tor/ligand interactions with target cells 
(Chalmin et al., 2010; Nolte-‘t Hoen et al., 
2009), b) transferring cell surface receptors 
(Baj-Krzyworzeka et al., 2006) and c) intra-
cellular proteins and RNAs delivery into re-
cipient cells (Putz et al., 2012; Zhang et al., 
2010). 
Different studies focused on target cells 
transformation by microvesicles, have shown 
acquisition of aggressive cancerous pheno-
types by a non-aggressive population of tu-
mor cells through microvesicles (Al-Nedawi 
et al., 2008), transformation of normal hema-
topoietic transplants through genomic insta-
bility induced by BCR-ABL positive mi-
crovesicles (Zhu et al., 2014) and repro-
gramming of hematopoietic progenitors by 
embryonic stem cells derived microvesicles 
(Ratajczak et al., 2006). 
Based on these findings, we chose umbil-
ical cord blood hematopoietic stem cells, as a 
remarkable source for stem cell transplanta-
tion, to be our target cell for leukemia cell 
microvesicles. We were interested to see 
whether these microvesicles have any affect 
hematopoietic stem cell survival or cause 
apoptosis.  
 
MATERIALS AND METHODS  
Human samples and cell line preparation 
Bone marrow aspiration was obtained 
from healthy volunteers (written informed 
consent was obtained) in accordance with 
ethical standards of the responsible commit-
tee on human experimentation in Tarbiat 
Modares University. Red blood cell lysis 
was done by ammonium chloride and the 
remaining cells were used for microvesicles 
isolation. 
Jurkat cells were maintained in RPMI 
1640 containing 15 % fetal bovine serum, 
100 U/ml penicillin and 100 µg/ml strepto-
mycin at 37 °C, 5 % CO2 and 90 % humidity. 
 
Microvesicles isolation 
Both normal bone marrow cells and 
Jurkat cells were transferred to RPMI 1640 
supplemented with 0.6 % bovine serum al-
bumin overnight. Then, the supernatant was 
collected and freshly used. Cell-free superna-
tants were obtained by a 2,000 rpm centrifu-
gation at 4 °C for 10 minutes. Cell debris and 
apoptotic bodies were excluded by 10,000 g 
centrifugation at 4 °C for 20 minutes. Macro-
vesicles pallets were achieved after 20,000 g 
centrifugation at 4 °C for one hour and final-
ly, the microvesicles were washed in phos-
phate buffered saline after repeated centrifu-
gation at 20,000 g. The pellets were used 
freshly for both calculating protein concen-
tration by Bradford assay and co-incubation 
with target cells. 
 
Microvesicles transmission electron  
microscopy 
Isolated microvesicles were stained with 
2 % -uranyl acetate on formvar-carbon coat-
ed grids as a negative stain. After drying, the 
grid was placed in electron microscope to 
provide transmission images.  
 
Hematopoietic stem cells sorting 
Umbilical cord blood samples were ob-
tained from Iranian blood Transfusion Or-
ganization in CPDA1 reagent (written con-
sent was obtained). MACS technique was 
used to sort hematopoietic stem cells by 
CD34 magnetic immunobeads (Milteny Bio-
tec, Auburn, CA). Purity of the cells was an-
alyzed by flow cytometry. 
 
Co-incubation of hematopoietic stem cells 
and isolated Microvesicles 
55,000 sorted hematopoietic stem cells 
were treated with 20 µg/ml microvesicles 
from normal bone marrow cells (normal 
group) and Jurkat cells (leukemia group) in 
500 µl Stemline medium (Sigma-Aldrich) 
containing 50 ng/ml TPO (Pepro Tech) and 
FLT3 (ORF Genetics) recombinant proteins 
and were kept at 37 °C, 5 % CO2 and 90 % 
humidity for 7 days. In the control group, cells 
were incubated without any microvesicle. 
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Cell count 
After 7 days, the number of cells was 
evaluated in a hemocytometer chamber by 
using Trypan Blue. 
 
Flow cytometry analysis 
Cell viability was analyzed by 7AAD 
(PE-Texas Red, Sigma-Aldrich). CD34 (PE, 
eBiosciences) and CD45 (FITC, BD) anti-
bodies were used for cell staining to evaluate 
purity and also hematopoietic stem cell 
markers. CD2 and CD19 antibodies (both 
BD) were used to show lineage differentia-
tion. 
 
Quantitative real time PCR 
Total RNA was extracted using RNX 
Plus reagent (Sinagen, Iran) and cDNA was 
synthesized according to the instruction 
(Fermentase). Expression of P53, as a cell 
cycle gene and HPRT as a housekeeping 
gene, was analyzed by real time detection 
system (Applied Biosystems Plus one) using 
SYBR Green master mix (Takara, Japan) 
according to the manufacturer’s protocol. 
Both genes’ primer sequences are provided 
in Table 1. Relative gene expression fold 
change was calculated with 2(‐∆∆Ct) formu-
la. 
 
Table1: Primer sequences 
Gene 
name Primer sequence 
HPRT1-F 5'-CCT  GGC  GTC  GTG  ATT  AGT  G-3' 
HPRT1-R 5'-TCA  GTC  CTG  TCC  ATA  ATT  AGT  CC-3' 
P53-F 5'-GGA  GTA  TTT  GGA  TGA  CAG  AAA  C-3' 
P53-R 5'-GAT  TAC  CAC  TGG  AGT  CTT  C-3' 
 
Statistical analysis 
All experiments were replicated three 
times, independently and data was presented 
as mean ± SD. SPSS 22 software was used 
for one-way ANOVA analysis (for normal 
distributions) and Kruskal-Wallis test (for 
abnormal distributions). P<0.05 was consid-
ered statistically significant.  
RESULTS 
Transmission electron microscopy image 
confirming the size of isolated microvesicles 
As shown in Figure 1, microvesicles’ 
size on electron microscopy was less than 
1 µm, indicating the true protocol for isola-
tion and purification of microvesicles with a 
size range of 0.1-1 µm. 
 
 
Figure 1: Transmission electron microscopy im-
age of isolated microvesicles (6000X) 
 
 
Jurkat microvesicles retain the number of 
hematopoietic stem cells  
After 7 days, the number of hematopoiet-
ic stem cells treated with Jurkat microvesi-
cles was more than that in the other two 
groups (Figure 2) and this difference was 
statistically significant (P<0.05). However, 
the number of cells in control and normal 
groups was less than the first day seeding 
number.  
 
Figure 2: Cell count. Values are mean ± SD of 
three samples in each group 
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Jurkat microvesicles keep hematopoietic 
stem cells alive 
Flow cytometry analysis showed a higher 
range of viability in leukemia group in com-
parison with control and normal groups 
(P<0.05) (Figure 3a, b).  
 
 
Figure 3: Cell viability test. a) 7AAD staining re-
sults with blue histogram show one sample from 
leukemia group merged with red histogram. b) 
Viable cells values in three studied groups (mean 
± SD). 
 
 
Jurkat microvesicles do not change  
hematopoietic stem cell markers 
CD34 expression was not significantly 
different among studied groups (P>0.05) and 
was close to CD34 expression in the first day 
sorted hematopoietic stem cells. CD45 ex-
pression was still high. CD2 and CD19 ex-
pression were both in minimum range show-
ing no differentiation in stem cells during the 
treatment with microvesicles (Figure 4a-e). 
 
Jurkat microvesicles decrease P53 gene  
expression 
Quantitative real time PCR showed a de-
crease in P53 gene expression, normalized 
with HPRT, compared to control and normal 
groups (P=0.01) (Figure 5).  
 
 
Figure 4: Flow cytometry analysis for hemato-
poietic stem cell markers. a) Purity of first day 
sorted hematopoietic stem cells. b) Gated popu-
lation. c) CD45 expression after treatment. d) 
CD2 and CD19 expression after treatment. e) 
CD 34 expression after treatment in all studied 
groups. 
 
 
 
Figure 5: P53 gene expression fold change in 
studied groups after treating with microvesicles 
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DISCUSSION  
Microvesicles take part in numerous 
physiological events. Behind of intercellular 
communications, as one of the most im-
portant functions, they are also involved in 
regulation of programmed cell death (Hus-
sein et al., 2007; Furie and Furie, 2008; Dis-
tler et al., 2005).  Generally, cells shed mi-
crovesicles to protect against intracellular 
stress (Doormal et al., 2009). Microvesicles 
containing caspase3, one of the main execu-
tioner enzymes of apoptosis, are present in 
conditioned medium of viable cell culture; 
but this enzyme is not detectable in those 
cells microvesicles originated from (Boing et 
al., 2008; Sapet et al., 2006). Thus, cells may 
escape from apoptosis by releasing these mi-
crovesicles. On the other hand, some studies 
especially the one by Valenti and colleagues 
showed the anti-apoptotic effect of tumor 
cell microvesicles on target cells. They 
showed that CD14+ cells from peripheral 
blood were resistant to apoptosis induced by 
microvesicles released from tumor cells such 
as melanoma and colorectal carcinoma cell 
lines (Valenti et al., 2006). However, previ-
ously they showed apoptosis induction in 
activated T cells (Jurkat) by tumor cells mi-
crovesicles (Andreola et al., 2002; Huber et 
al., 2005).  Also, another study showed a de-
creased level of P53 gene expression in 
mono nuclear cells treated with leukemia cell 
microvesicles (K562) (Zhu et al., 2014). The 
ability of P53 to promote cell cycle arrest 
and apoptosis is well known and appears to 
induce apoptosis by multiple pathways 
(Benchimol, 2001). In concordance with the 
above-mentioned research, we showed the 
anti-apoptotic effect of leukemia cell mi-
crovesicles on target cells. Our results indi-
cated lower level of P53 gene expression in 
umbilical cord blood hematopoietic stem 
cells treated with Jurkat cell microvesicles in 
comparison with control and normal groups.  
In addition, this study is the first investi-
gation seeking the effect of leukemic cell 
microvesicles directly on umbilical cord 
blood hematopoietic stem cells which are 
among the most important sources for stem 
cell transplantation. We showed high viabil-
ity and survival of these cells when com-
pared with other groups which was close to 
the seeding number on day 0. These results 
were much more brilliant when we observed 
a high expression of CD34 and CD45 mark-
ers but not lineage markers such as CD2 and 
CD19, indicating that umbilical cord blood 
hematopoietic stem cells, which were treated 
with Jurkat cell microvesicles, expressed im-
portant hematopoietic stem cell markers after 
7 days. Thus, we can conclude that this 
treatment is not able to promote differentia-
tion in studied stem cells.  
We designed our experiment based on 
the role of microvesicles in inducing poten-
tial effects on target cells. To achieve this 
goal, the conditioned medium for treating 
hematopoietic stem cells with microvesicles, 
included FLT3 and TPO cytokines and 
lacked Stem Cell Factor according to Pi-
acibello’s study (Piacibello et al., 1997) to 
have the fewest level of expansion and the 
highest level of colony formation during the 
first two weeks. It was the most important 
check point in our work to remark mi-
crovesicles power to show their effects.  
In summary, we showed that Jurkat cell 
microvesicles are able to induce apoptosis 
resistance in umbilical cord blood hemato-
poietic stem cells. The results indicated rea-
sonably viable number of hematopoietic 
stem cells in presence of leukemia mi-
crovesicles which still expressed more than 
90 % CD34 and CD45 markers without dif-
ferentiation.  
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